ACTRN12614000049673
Not yet recruiting
Phase 3
itrates as a potential therapeutic option for bone fragility in chronic kidney disease - a randomised, double blind placebo controlled trial
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- The University of Melbourne
- Enrollment
- 60
- Status
- Not yet recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Participants willl have both stage 3 or 4 CKD and either
- •osteopenia or osteoporosis
Exclusion Criteria
- •Minimal trauma fractures
- •Uncorrected vitamin D deficiency (\< 50 nmol/L)
- •PTH \> 15 pmols/L
- •Metabolic bone diseases
- •Prednisolone \> 5 mgs/d
- •Unexplained elevation of serum alkaline phosphatase
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
ew Therapies for bone and cartilage defects using bone marrownot applicable1002321310046304NL-OMON43408Orthopaedie200
Not yet recruiting
Not Applicable
Clinical study for efficacy and safety of bone marrow derived cell concentrate and allogenic dermal matrix complex therapy in diabetic foot ulcerEndocrine, nutritional and metabolic diseasesKCT0009122Soon Chun Hyang University Hospital Bucheon58
Completed
Not Applicable
Validation of a Production Method of Stem Cell Isolated From the Nasal Cavity for an Innovative Cell Therapy of Cleft PalateCleft PalateNCT02900014Assistance Publique Hopitaux De Marseille2
Not yet recruiting
Not Applicable
Research for the development of bone regenerative medicine products using human alveolar bone derived immature osteoblast.Dental cyst, apical periodontitisJPRN-UMIN000050839Tohoku University30
Completed
Phase 1
Study To Determine The Effects Of Doses Of Relacatib On The Metabolism Of Acetaminophen, Ibuprofen And AtorvastatinOsteoarthritisNCT00411190GlaxoSmithKline32